{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:57:41Z","timestamp":1783637861807,"version":"3.55.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T00:00:00Z","timestamp":1705622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T00:00:00Z","timestamp":1705622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R34DA057160"],"award-info":[{"award-number":["R34DA057160"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Buprenorphine is a highly effective medication for opioid use disorder that is underused by health care professionals (HCPs). Medications for opioid use disorder (MOUD) misinformation may be an important barrier to buprenorphine access, but most implementation strategies have aimed to reduce negative attitudes towards patients with opioid use disorder (OUD) rather than misinformation specific to buprenorphine use. In this study, we assessed the degree to which HCPs endorsed misinformation related to buprenorphine, and whether this is associated with willingness to provide care to patients with OUD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In September-December of 2022, we surveyed HCPs practicing in Ohio (n\u2009=\u2009409). Our primary outcomes included a previously validated 5-item measure of HCP willingness to treat patients with OUD, and three other measures of willingness. Our key independent variable was a study-developed 5-item measure of endorsement of misinformation related to buprenorphine, which assessed beliefs in buprenorphine\u2019s efficacy in managing withdrawal symptoms and reducing overdose deaths as well as beliefs about the role of buprenorphine in achieving remission. We computed descriptive and bivariable statistics and fit regression models predicting each outcome of interest.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>On average, HCPs scored 2.34 out of 5.00 (SD\u2009=\u20090.80) on the composite measure of buprenorphine misinformation. 48.41% of participants endorsed at least one piece of misinformation. The most endorsed items were that buprenorphine is ineffective at reducing overdose deaths (M\u2009=\u20092.75, SD\u2009=0\u2009.98), and that its use substitutes one drug for another (M\u2009=\u20092.41, SD\u2009=\u20091.25). HCP endorsement of buprenorphine misinformation significantly and negatively predicted willingness to work with patients with OUD (b\u2009=\u2009\u2212\u00a00.34; 95% CI \u2212\u00a00.46, \u2212\u00a00.21); intentions to increase time spent with this patient population (b\u2009=\u2009\u2212\u00a00.36; 95% CI \u2212\u00a05.86, \u2212\u00a01.28); receipt of an X-waiver (OR\u2009=\u20090.54, 95% CI 0.38, 0.77); and intention to get an X-waiver (OR: 0.56; 95% CI: 0.33\u22120.94).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Misinformation is common among HCPs and associated with lower willingness to treat patients with OUD. Implementation strategies to increase MOUD use among HCPs should specifically counter misinformation related to buprenorphine.<\/jats:p>\n                <jats:p><jats:italic>Clinical Trial Registration<\/jats:italic>: Clinicaltrials.gov, NCT05505227. Registered 17 August 2022, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05505227\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05505227<\/jats:ext-link><\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13722-024-00436-y","type":"journal-article","created":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T12:02:42Z","timestamp":1705665762000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Buprenorphine misinformation and willingness to treat patients with opioid use disorder among primary care-aligned health care professionals"],"prefix":"10.1186","volume":"19","clinical-trial-number":[{"clinical-trial-number":"nct05505227","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2091-1891","authenticated-orcid":false,"given":"Berkeley","family":"Franz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay Y.","family":"Dhanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O. Trent","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel L.","family":"Brook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheyenne","family":"Fenstemaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet E.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,19]]},"reference":[{"key":"436_CR1","unstructured":"Effective treatments for opioid addiction | national institute on drug abuse (NIDA). https:\/\/nida.nih.gov\/publications\/effective-treatments-opioid-addiction"},{"issue":"3","key":"436_CR2","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7326\/M17-3107","volume":"169","author":"MR Larochelle","year":"2018","unstructured":"Larochelle MR, Bernson D, Land T, Stopka TJ, Wang N, Xuan Z, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann Intern Med. 2018;169(3):137\u201345.","journal-title":"Ann Intern Med"},{"key":"436_CR3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.20622","author":"SE Wakeman","year":"2020","unstructured":"Wakeman SE, Larochelle MR, Ameli O, Chaisson CE, McPheeters JT, Crown WH, et al. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open. 2020. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.20622.","journal-title":"JAMA Netw Open"},{"issue":"6","key":"436_CR4","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1086\/432888","volume":"41","author":"LE Sullivan","year":"2005","unstructured":"Sullivan LE, Fiellin DA. Buprenorphine Its role in preventing HIV transmission and improving the care of HIV-infected patients with opioid dependence. Clinical Infectious Diseases. 2005;41(6):891\u20136.","journal-title":"Clinical Infectious Diseases"},{"key":"436_CR5","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.drugalcdep.2014.03.006","volume":"139","author":"EJ Edelman","year":"2014","unstructured":"Edelman EJ, Chantarat T, Caffrey S, Chaudhry A, O\u2019Connor PG, Weiss L, et al. The impact of buprenorphine\/naloxone treatment on hiv risk behaviors among HIV-infected opioid-dependent patients. Drug Alcohol Depend. 2014;139:79.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"436_CR6","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jsat.2007.08.004","volume":"35","author":"LE Sullivan","year":"2008","unstructured":"Sullivan LE, Moore BA, Chawarski MC, Pantalon MV, Barry D, O\u2019Connor PG, et al. Buprenorphine\/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors. J Subst Abuse Treat. 2008;35(1):87\u201392.","journal-title":"J Subst Abuse Treat"},{"issue":"6","key":"436_CR7","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1377\/hlthaff.2019.01622","volume":"9","author":"M Olfson","year":"2020","unstructured":"Olfson M, Zhang V, Schoenbaum M, King M. Buprenorphine treatment by primary care providers, psychiatrists, addiction specialists and others. Health Aff. 2020;9(6):984\u201392.","journal-title":"Health Aff"},{"issue":"1","key":"436_CR8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/jrh.12569","volume":"38","author":"CHA Andrilla","year":"2022","unstructured":"Andrilla CHA, Patterson DG. Tracking the geographic distribution and growth of clinicians with a DEA waiver to prescribe buprenorphine to treat opioid use disorder. J Rural Health. 2022;38(1):87\u201392.","journal-title":"J Rural Health"},{"issue":"14","key":"436_CR9","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1001\/jama.2019.0834","volume":"321","author":"J Spetz","year":"2019","unstructured":"Spetz J, Toretsky C, Chapman S, Phoenix B, Tierney M. Nurse practitioner and physician assistant waivers to prescribe buprenorphine and state scope of practice restrictions. JAMA. 2019;321(14):1407\u20138.","journal-title":"JAMA."},{"key":"436_CR10","unstructured":"Medicated-Assisted Treatment Training Materials & Resources | SAMHSA. https:\/\/www.samhsa.gov\/medications-substance-use-disorders\/training-resources"},{"key":"436_CR11","doi-asserted-by":"publisher","first-page":"103786","DOI":"10.1016\/j.drugpo.2022.103786","volume":"110","author":"N Krawczyk","year":"2022","unstructured":"Krawczyk N, Rivera BD, Jent V, Keyes KM, Jones CM, Cerd\u00e1 M. Has the treatment gap for opioid use disorder narrowed in the US?: a yearly assessment from 2010 to 2019. Int J Drug Policy. 2022;110:103786.","journal-title":"Int J Drug Policy"},{"issue":"5","key":"436_CR12","doi-asserted-by":"publisher","first-page":"e2212419","DOI":"10.1001\/jamanetworkopen.2022.12419","volume":"5","author":"HJ Lanham","year":"2022","unstructured":"Lanham HJ, Papac J, Olmos DI, Heydemann EL, Simonetti N, Schmidt S, et al. Survey of barriers and facilitators to prescribing buprenorphine and clinician perceptions on the drug addiction treatment act of 2000 waiver. JAMA Netw Open. 2022;5(5):e2212419\u2013e2212419.","journal-title":"JAMA Netw Open."},{"key":"436_CR13","unstructured":"Medications for opioid use disorder save lives. medications for opioid use disorder save lives. 2019 May 16."},{"issue":"9","key":"436_CR14","doi-asserted-by":"publisher","first-page":"761","DOI":"10.3109\/10826084.2013.787101","volume":"48","author":"NE Hagemeier","year":"2013","unstructured":"Hagemeier NE, Gray JA, Pack RP. Prescription drug abuse: a comparison of prescriber and pharmacist perspectives. Subst Use Misuse. 2013;48(9):761\u20138.","journal-title":"Subst Use Misuse"},{"issue":"2","key":"436_CR15","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1080\/08897077.2011.630944","volume":"33","author":"CE Keller","year":"2012","unstructured":"Keller CE, Ashrafioun L, Neumann AM, Van Klein J, Fox CH, Blondell RD. Practices, perceptions, and concerns of primary care physicians about opioid dependence associated with the treatment of chronic pain. Subst Abus. 2012;33(2):103\u201313.","journal-title":"Subst Abus"},{"issue":"1","key":"436_CR16","first-page":"99","volume":"7","author":"RN Jamison","year":"2016","unstructured":"Jamison RN, Scanlan E, Matthews ML, Jurcik DC, Ross EL. Attitudes of primary care practitioners in managing chronic pain patients prescribed opioids for pain: a prospective longitudinal controlled trial. Pain Med. 2016;7(1):99\u2013113.","journal-title":"Pain Med"},{"key":"436_CR17","doi-asserted-by":"publisher","DOI":"10.2147\/SAR.S304566","author":"A Cheetham","year":"2022","unstructured":"Cheetham A, Picco L, Barnett A, Lubman DI, Nielsen S. The impact of stigma on people with opioid use disorder, opioid treatment, and policy. Subst Abuse Rehabil. 2022. https:\/\/doi.org\/10.2147\/SAR.S304566.","journal-title":"Subst Abuse Rehabil"},{"issue":"1\u20132","key":"436_CR18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.drugalcdep.2013.02.018","volume":"131","author":"LC Van Boekel","year":"2013","unstructured":"Van Boekel LC, Brouwers EPM, Van Weeghel J, Garretsen HFL. Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: systematic review. Drug Alcohol Depend. 2013;131(1\u20132):23\u201335.","journal-title":"Drug Alcohol Depend."},{"issue":"4","key":"436_CR19","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1080\/08897077.2019.1640833","volume":"40","author":"B Allen","year":"2019","unstructured":"Allen B, Nolan ML, Paone D. Underutilization of medications to treat opioid use disorder: What role does stigma play? Subst Abus. 2019;40(4):459\u201365.","journal-title":"Subst Abus"},{"issue":"14","key":"436_CR20","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1080\/10826084.2021.1975749","volume":"56","author":"EF Madden","year":"2021","unstructured":"Madden EF, Prevedel S, Light T, Sulzer SH. Intervention stigma toward medications for opioid use disorder: a systematic review. Subst Use Misuse. 2021;56(14):2181\u2013201.","journal-title":"Subst Use Misuse"},{"key":"436_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadr.2023.100138","volume":"6","author":"A Carl","year":"2023","unstructured":"Carl A, Pasman E, Broman MJ, Lister JJ, Agius E, Resko SM. Experiences of healthcare and substance use treatment provider-based stigma among patients receiving methadone. Drug Alcohol Dependence Rep. 2023;6: 100138.","journal-title":"Drug Alcohol Dependence Rep"},{"key":"436_CR22","doi-asserted-by":"publisher","DOI":"10.1177\/11782218221103859","author":"J Dickson-Gomez","year":"2022","unstructured":"Dickson-Gomez J, Spector A, Weeks M, Galletly C, McDonald M, Green Montaque HD. You\u2019re not supposed to be on it forever\u201d: medications to treat opioid use disorder (MOUD) related stigma among drug treatment providers and people who use opioids. Subst Abuse. 2022. https:\/\/doi.org\/10.1177\/11782218221103859.","journal-title":"Subst Abuse"},{"issue":"4","key":"436_CR23","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1080\/15504263.2013.835165","volume":"9","author":"J Avery","year":"2013","unstructured":"Avery J, Dixon L, Adler D, Oslin D, Hackman A, First M, et al. Psychiatrists attitudes toward individuals with substance use disorders and serious mental illness. J Dual Diagn. 2013;9(4):322\u20136.","journal-title":"J Dual Diagn"},{"key":"436_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2016.05.010","author":"A Kennedy-Hendricks","year":"2016","unstructured":"Kennedy-Hendricks A, Busch SH, McGinty EE, Bachhuber MA, Niederdeppe J, Gollust SE, et al. Primary care physicians\u2019 perspectives on the prescription opioid epidemic. Drug Alcohol Depend. 2016. https:\/\/doi.org\/10.1016\/j.drugalcdep.2016.05.010.","journal-title":"Drug Alcohol Depend"},{"key":"436_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005470.pub2","author":"R Baker","year":"1996","unstructured":"Baker R, Camosso-Stefinovic J, Gillies C, Shaw EJ, Cheater F, Flottorp S, et al. Tailored interventions to overcome identified barriers to change: effects on professional practice and health care outcomes. Cochrane Database Syst Rev. 1996. https:\/\/doi.org\/10.1002\/14651858.CD005470.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"436_CR26","unstructured":"How to Address COVID-19 Vaccine Misinformation | CDC. https:\/\/www.cdc.gov\/vaccines\/covid-19\/health-departments\/addressing-vaccine-misinformation.html"},{"issue":"8","key":"436_CR27","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1080\/10826084.2022.2079133","volume":"57","author":"R Garett","year":"2022","unstructured":"Garett R, Young SD. The role of misinformation and stigma in opioid use disorder treatment uptake. Subst Use Misuse. 2022;57(8):1332\u20136.","journal-title":"Subst Use Misuse"},{"issue":"1","key":"436_CR28","first-page":"23","volume":"18","author":"VJR Suboxone","year":"2018","unstructured":"Suboxone VJR. Rationale, science, misconceptions. Ochsner J. 2018;18(1):23.","journal-title":"Ochsner J"},{"issue":"22","key":"436_CR29","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMp1402780","volume":"370","author":"ND Volkow","year":"2014","unstructured":"Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies\u2013tackling the opioid-overdose epidemic. N Engl J Med. 2014;370(22):2063\u20136.","journal-title":"N Engl J Med"},{"key":"436_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108593","volume":"132","author":"NM Brousseau","year":"2022","unstructured":"Brousseau NM, Farmer H, Karpyn A, Laurenceau JP, Kelly JF, Hill EC, et al. Qualitative characterizations of misinformed disclosure reactions to medications for opioid use disorders and their consequences. J Subst Abuse Treat. 2022;132: 108593.","journal-title":"J Subst Abuse Treat"},{"key":"436_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12875-019-1047-z","author":"DL Louie","year":"2019","unstructured":"Louie DL, Assefa MT, McGovern MP. Attitudes of primary care physicians toward prescribing buprenorphine: a narrative review. BMC Fam Pract. 2019. https:\/\/doi.org\/10.1186\/s12875-019-1047-z.","journal-title":"BMC Fam Pract"},{"issue":"11","key":"436_CR32","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1097\/ACM.0000000000002883","volume":"94","author":"A Muzyk","year":"2019","unstructured":"Muzyk A, Smothers ZPW, Akrobetu D, Ruiz Veve J, MacEachern M, Tetrault JM, et al. Substance use disorder education in medical schools: a scoping review. Acad Med. 2019;94(11):1825\u201334.","journal-title":"Acad Med"},{"issue":"11","key":"436_CR33","doi-asserted-by":"publisher","first-page":"1002969","DOI":"10.1371\/journal.pmed.1002969","volume":"16","author":"AC Tsai","year":"2019","unstructured":"Tsai AC, Kiang MV, Barnett ML, Beletsky L, Keyes KM, McGinty EE, et al. Stigma as a fundamental hindrance to the United States opioid overdose crisis response. PLoS Med. 2019;16(11):1002969. https:\/\/doi.org\/10.1371\/journal.pmed.1002969.","journal-title":"PLoS Med"},{"key":"436_CR34","unstructured":"Care I of M (US) C on the F of P, Donaldson MS, Yordy KD, Lohr KN, Vanselow NA. 1996. Defining primary care. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK232631\/"},{"issue":"1","key":"436_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13722-021-00242-w","volume":"16","author":"B Franz","year":"2021","unstructured":"Franz B, Dhanani LY, Brook DL. Physician blame and vulnerability: novel predictors of physician willingness to work with patients who misuse opioids. Addict Sci Clin Pract. 2021;16(1):1\u20139. https:\/\/doi.org\/10.1186\/s13722-021-00242-w.","journal-title":"Addict Sci Clin Pract"},{"issue":"8","key":"436_CR36","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1176\/appi.ps.202000529","volume":"72","author":"B Franz","year":"2021","unstructured":"Franz B, Dhanani LY, Miller WC. Rural-Urban differences in physician bias toward patients with opioid use disorder. Psychiatr Serv. 2021;72(8):874\u20139.","journal-title":"Psychiatr Serv"},{"key":"436_CR37","unstructured":"Ohio Rural Health Improvement Plan\u2014Ohio rural health association. https:\/\/www.ohioruralhealth.org\/ohio-rural-health-improvement-plan"},{"key":"436_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadr.2023.100133","volume":"6","author":"C Heidbreder","year":"2023","unstructured":"Heidbreder C, Fudala PJ, Greenwald MK. History of the discovery, development, and FDA-approval of buprenorphine medications for the treatment of opioid use disorder. Drug and Alcohol Dependence Rep. 2023;6: 100133.","journal-title":"Drug and Alcohol Dependence Rep"},{"issue":"4","key":"436_CR39","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1370\/afm.2099","volume":"15","author":"CHA Andrilla","year":"2017","unstructured":"Andrilla CHA, Coulthard C, Larson EH. Barriers rural physicians face prescribing buprenorphine for opioid use disorder. Ann Fam Med. 2017;15(4):359\u201362.","journal-title":"Ann Fam Med"},{"issue":"2","key":"436_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ssmqr.2022.100161","volume":"1","author":"EF Madden","year":"2022","unstructured":"Madden EF, Barker KK, Guerra J, Villanueva C, Sulzer SH. Variation in intervention stigma among medications for opioid use disorder. SSM\u2014Qual Res Health. 2022;1(2): 100161.","journal-title":"SSM\u2014Qual Res Health"},{"issue":"13","key":"436_CR41","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1080\/10410236.2020.1794553","volume":"36","author":"N Walter","year":"2021","unstructured":"Walter N, Brooks JJ, Saucier CJ, Suresh S. Evaluating the impact of attempts to correct health misinformation on social media: a meta-analysis. Health Commun. 2021;36(13):1776\u201384.","journal-title":"Health Commun"},{"key":"436_CR42","unstructured":"Americans trust in scientists, other groups declines | pew research center. https:\/\/www.pewresearch.org\/science\/2022\/02\/15\/americans-trust-in-scientists-other-groups-declines\/"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-024-00436-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-024-00436-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-024-00436-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T12:06:38Z","timestamp":1705665998000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-024-00436-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,19]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["436"],"URL":"https:\/\/doi.org\/10.1186\/s13722-024-00436-y","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,19]]},"assertion":[{"value":"2 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ohio University Institutional Review Board in 2022.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have provided consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7"}}